Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations

被引：0

作者：

Moreno, Victor

Loriot, Yohann

Valderrama, Begona Perez

Beato, Carmen

Vano, Yann-Alexandre

Fleming, Mark T.

Duran, Ignacio

Siena, Salvatore

Tolbert, Jaszianne A.

OHagan, Anne

Akapame, Sydney

Lau, Yvonne Y.

Geoffrois, Lionnel

Tagawa, Scott T.

Mellado, Begona

Siefker-Radtke, Arlene O.

机构：

[1] Fdn Jimenez Diaz Univ Hosp, START Madrid FJD, Madrid, Spain

[2] Univ Paris Saclay, Univ Paris Sud, Inst Gustave Roussy, Villejuif, France

[3] Hosp Univ Virgen del Rocio, Dept Med Oncol, Seville, Spain

[4] Hosp Virgen de la Macarena, Med Oncol Serv, Seville, Spain

[5] Univ Paris 05, Georges Pompidou Hosp, Dept Med Oncol, Paris, France

[6] US Oncol Res, Virginia Oncol Associates, Norfolk, VA USA

[7] Hosp Univ Marques de Valdecilla, Santander, Spain

[8] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy

[9] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy

[10] Janssen Res & Dev LLC, Titusville, NJ USA

[11] Janssen Res & Dev LLC, Spring House, PA USA

[12] Inst Cancerol Lorraine, Dept Med Oncol, Vandoeuvre Les Nancy, France

[13] Weill Cornell Med Ctr, New York, NY USA

[14] Univ Barcelona, Hosp Clin Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain

[15] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

511

引用

页数：2